- Home
- HQI vs IVVD Comparison
HQI vs IVVD Comparison
Compare HQI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HQI | IVVD |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.1M | 201.9M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HQI | IVVD |
|---|---|---|
| Price | $13.89 | $0.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.00 | $8.75 |
| AVG Volume (30 Days) | 7.0K | ★ 2.9M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 73.08 | ★ 79.02 |
| EPS | ★ 0.11 | N/A |
| Revenue | $30,640,000.00 | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | $0.46 | $41.42 |
| P/E Ratio | $116.45 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $7.38 | $0.49 |
| 52 Week High | $14.54 | $3.07 |
Technical Indicators
Market Signals| Indicator | HQI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 38.19 |
| Support Level | $12.03 | N/A |
| Resistance Level | $13.42 | $1.01 |
| Average True Range (ATR) | 0.66 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 31.53 | 28.18 |
Price Performance
Historical ComparisonAbout HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.